Jeffrey Fong Ting Chau

Jeffrey Fong Ting Chau

Auto-generated profile, based on publicly available information

Jeffrey Fong Ting Chau

Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2021 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
BCBrian Hon Yin Chung
Brian Hon Yin Chung
JCJeffrey Fong Ting Chau
Jeffrey Fong Ting Chau
GWGane Ka-Shu Wong
Gane Ka-Shu Wong
Precision medicine initiatives are being launched worldwide, each with the capacity to sequence many thousands to millions of human genomes. At the strategic planning level, all are debating the extent to which these resources will be directed towards rare diseases (and cancers) versus common diseases. However, these are not mutually exclusive choices. The organizational and governmental infrastructure created for rare diseases is extensible to common diseases. As we will explain, the underlying technology can also be used to identify drug targets for common diseases with a strategy focused on naturally occurring human knockouts. This flips on its head the prevailing modus operandi of studying people with diseases of interest, shifting the onus to defining traits worth emulating by pharmaceuticals, and searching phenotypically for people with these traits. This also shifts the question of what is rare or common from the many underlying causes to the possibility of a common final pathway.

18 February 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MYMullin Ho Chung Yu
Mullin Ho Chung Yu
MCMarcus Chun Yin Chan
Marcus Chun Yin Chan
CCClaudia Ching Yan Chung
Claudia Ching Yan Chung
ALAndrew Wang Tat Li
Andrew Wang Tat Li
CYChara Yin Wa Yip
Chara Yin Wa Yip
BCBrian Hon Yin Chung
Brian Hon Yin Chung
Preemptive pharmacogenetic testing has the potential to improve drug dosing by providing point-of-care patient genotype information. Nonetheless, its implementation in the Chinese population is limited by the lack of population-wide data. In this study, secondary analysis of exome sequencing data was conducted to study pharmacogenomics in 1116 Hong Kong Chinese. We aimed to identify the spectrum of actionable pharmacogenetic variants and rare, predicted deleterious variants that are potentially actionable in Hong Kong Chinese, and to estimate the proportion of dispensed drugs that may potentially benefit from genotype-guided prescription. The projected preemptive pharmacogenetic testing prescription impact was evaluated based on the patient prescription data of the public healthcare system in 2019, serving 7.5 million people. Twenty-nine actionable pharmacogenetic variants/ alleles were identified in our cohort. Nearly all (99.6%) subjects carried at least one actionable pharmacogenetic variant, whereas 93.5% of subjects harbored at least one rare deleterious pharmacogenetic variant. Based on the prescription data in 2019, 13.4% of the Hong Kong population was prescribed with drugs with pharmacogenetic clinical practice guideline recommendations. The total expenditure on actionable drugs was 33,520,000 USD, and it was estimated that 8,219,000 USD (24.5%) worth of drugs were prescribed to patients with an implicated actionable phenotype. Secondary use of exome sequencing data for pharmacogenetic analysis is feasible, and preemptive pharmacogenetic testing has the potential to support prescription decisions in the Hong Kong Chinese population.

21 March 2022 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
JCJeffrey Fong Ting Chau
Jeffrey Fong Ting Chau
MYMullin Ho Chung Yu
Mullin Ho Chung Yu
MCMartin Man Chun Chui
Martin Man Chun Chui
CYCyrus Chun Wing Yeung
Cyrus Chun Wing Yeung
AKAaron Wing Cheung Kwok
Aaron Wing Cheung Kwok
CTClara Sze-man TANG
Clara Sze-man TANG
Traditional carrier screening has been utilized for the detection of carriers of genetic disorders. Since a comprehensive assessment of the carrier frequencies of recessive conditions in the Southern Chinese population is not yet available, we performed a secondary analysis on the spectrum and carrier status for 315 genes causing autosomal recessive disorders in 1543 Southern Chinese individuals with next-generation sequencing data, 1116 with exome sequencing and 427 with genome sequencing data. Our data revealed that 1 in 2 people (47.8% of the population) was a carrier for one or more recessive conditions, and 1 in 12 individuals (8.30% of the population) was a carrier for treatable inherited conditions. In alignment with current American College of Obstetricians and Gynecologists (ACOG) pan-ethnic carrier recommendations, 1 in 26 individuals were identified as carriers of cystic fibrosis, thalassemia, and spinal muscular atrophy in the Southern Chinese population. When the >1% expanded carrier screening rate recommendation by ACOG was used, 11 diseases were found to meet the criteria in the Southern Chinese population. Approximately 1 in 3 individuals (35.5% of the population) were carriers of these 11 conditions. If the 1 in 200 carrier frequency threshold is used, and additional seven genes would meet the criteria, and 2 in 5 individuals (38.7% of the population) would be detected as a carrier. This study provides a comprehensive catalogue of the carrier spectrum and frequency in the Southern Chinese population and can serve as a reference for careful evaluation of the conditions to be included in expanded carrier screening for Southern Chinese people.

22 November 2020 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
MYMullin Ho Chung Yu
Mullin Ho Chung Yu
CMChristopher Chun Yu Mak
Christopher Chun Yu Mak
JFJasmine Lee Fong Fung
Jasmine Lee Fong Fung
MLMianne Lee
Mianne Lee
MTMandy Ho Yin Tsang
Mandy Ho Yin Tsang
BCBrian Hon Yin Chung
Brian Hon Yin Chung